AMP Amphion Innovations Plc

RNS Number:2505E
Amphion Innovations PLC
08 June 2006


               Amphion Innovations plc Annual General Meeting



                            Trading Update





London, UK, 8 June 2006 - The Annual General Meeting of Amphion Innovations plc
(LSE: AMP), the developer of companies in the life sciences and medical
technology sectors, will be held in London today.  We are providing the
following trading update summarising promising progress made regarding some of
our Partner Companies following on from the preliminary results announcement of
8 March 2006:



Durham Scientific Crystals, Ltd.



We are delighted to announce that Durham Scientific Crystals (DSC) this past
month won the prestigious North East Business Association's Regional Innovation
Company of the Year Award for 2006, sponsored by Barclay's Bank.  DSC had
previously won the North East Business Association's regional "Technology
Company of the Year" award in 2005, sponsored by O2.  Based in England's North
East region, DSC is advancing world-leading technology developed at Durham
University, dedicated to the field of medical imaging.



DSC also recently won a development contract worth #680,000 (approximately US
$1.3 million) from Cenamps (the Centre of Excellence for Nano, Micro and
Photonics Systems) to create a new product.  DSC will retain rights to both the
product and the IP resulting from its creation.



Says Mike Pitkethly, CEO of Cenamps, "Durham Scientific Crystals has
demonstrated a continued ability to innovate boldly and with great success.
Cenamps  is delighted to support the continued development of a regional company
that has world-wide potential."



Motif BioSciences, Inc.



Motif recently announced a relationship with the Shafallah Centre for Children
with Special Needs, which opened last month in Doha, Qatar.  Motif BioSciences,
Inc., played an instrumental role in the design and development of the Shafallah
Centre's Genetics Medical Centre, assisting in the procurement, identifying
leading instrument vendors, and assisting in the installation of a
first-of-its-kind genetics laboratory dedicated to conducting research on
disorders that afflict the children of Qatar.



Motif is delighted to today announce the hire of Zaki Hosny as deputy chairman
and chief executive officer.  Mr. Hosny comes to Motif from Merck and Company,
Inc., where he most recently held the position of vice president of marketing
and operations for Europe, the Middle East and Africa.  In that role, he was
responsible for the development of marketing strategies for the entire product
portfolio of the region.  Prior to that he was the vice president and regional
director for Merck's mid-European region, and during that time he successfully
supervised business units with sales of over $1 billion.



Axcess International Inc.



AXCESS International, Inc., a leading provider of Radio Frequency Identification
(RFID) systems, last week completed an additional capital raise of $1.2 million,
bringing the total raised in the recent campaign to $3.5 million.  The funds are
to be used in part to complete the development of a new RFID product designed to
further exploit AXCESS' existing markets utilising asset, personnel, and vehicle
tagging.



AXCESS booked record RFID revenue of $453,563 for the first quarter of 2006, an
increase of 88% from the same quarter in 2005 and 9% from the fourth quarter of
2005.



On 6 June 2006, AXCESS announced a solution for managing and securing critical
computer assets which hold privacy data.  The ActiveTagTM RFID solution is
applicable to data centres, record departments and enterprise operations where
computer assets must be accounted for and protected to be in compliance with
Federal and State Laws.



Supertron, Inc.



Supertron presented at the May 2006 show of the International Society for
Magnetic Resonance in Medicine (ISMRM), where they displayed the first-ever
commercially available superconducting coils for magnetic resonance imaging
(MRI) machines.  The products had an outstanding reception and Supertron expects
them to ship later in 2006.



WellGen, Inc.



Amphion mourns with great sorrow the sudden and unexpected passing last week of
Dr. David Evans, CEO of WellGen.  Our thoughts remain with his co-workers and
his family.



WellGen today announces the addition to its management team of Steve Sisk as
director of clinical operations.  Steve Sisk has a background including more
than 10 years of pharmaceutical and biotech industry experience (including Novo
Nordisk, Nektar Therapeutics and Applied Biosystems) involving CRO management
and negotiations, clinical study planning and the execution and direction of
large cross-functional development teams.  Steve received his BS in plant
genetics from Cornell University and his MS from the University of Wisconsin,
where he specialised in plant biochemistry and natural products drugs.



Richard Mansell-Jones, Chairman of Amphion, said:



"We are delighted with the strong progress made by our Partner Companies since
the March release of our preliminaries.



"We look towards the remainder of 2006 with great confidence."





Enquiries:


Amphion Innovations plc
Richard Morgan, Chief Executive                      +1 (212) 210-6224
Aaron Kwittken, Media Relations                      +1 (646) 747-7144

Financial Dynamics                                   +44 207 269 7169
Ben Atwell
John Gilbert



Notes to editors:



About Amphion Innovations plc

Amphion Innovations plc is quoted on AIM market of the London Stock Exchange
under the symbol AMP.  Amphion's business is the formation, financing,
management and development of life sciences and technology companies, working in
partnership with corporations, governments, universities and entrepreneurs
seeking to commercialise their intellectual property.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGMAKFKQABKKOAK

Amphion Innovations (LSE:AMP)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024

Amphion Innovations (LSE:AMP)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024